drugset / Trial / NCT02511990
A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This is a phase 1 clinical trial to evaluate the safety, pharmacokinetics and the antiretroviral effects of the highly neutralizing anti-HIV-1 monoclonal antibody 10-1074 in HIV-infected and HIV-uninfected individuals.
Timeline
- Start
- 2015-07
- Primary completion
- 2016-12
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zinlirvimab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Zinlirvimab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Zinlirvimab | Monoclonal antibody | 30 mg/kg | Intravenous |